Cabometyx (cabozantinib) — Medica

Initial criteria

• age ≥ 18 years
• patient has been previously treated with at least one systemic regimen (e.g., atezolizumab, bevacizumab, tremelimumab, durvalumab, sorafenib, lenvatinib, or nivolumab)

Approval duration

1 year